1015, 926 - 5 Avenue SW
Calgary, AB T2P 0N7
Branche: Drug Manufacturers—Specialty & Generic
|Mr. Ron Mayron||Exec. Chairman||207k||N/A||1963|
|Ms. Iris Bincovich||CEO & Director||361k||N/A||1969|
|Mr. Yoram Drucker||Founder, Exec. VP of Bus. Devel. & Director||261k||N/A||1966|
|Mr. Nelson Harvey Halpern F.C.A., FCPA||Chief Financial Officer||41k||N/A||1958|
|Mr. Nir Avram B.Sc., M.Sc.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Moshe Hukaylo||Chief Financial Officer of InnoCan Pharma Ltd.||N/A||N/A||N/A|
|Mr. Eyal Flom L.L.M., M.B.A.||Director & Company Sec.||N/A||N/A||1966|
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.
InnoCan Pharma Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.